245 related articles for article (PubMed ID: 19255962)
21. Factors influencing route of administration for epoetin treatment among hemodialysis patients in the United States.
Thamer M; Zhang Y; Kaufman J; Stefanik K; Cotter DJ
Am J Kidney Dis; 2006 Jul; 48(1):77-87. PubMed ID: 16797389
[TBL] [Abstract][Full Text] [Related]
22. Dose-finding study of peginesatide for anemia correction in chronic kidney disease patients.
Macdougall IC; Wiecek A; Tucker B; Yaqoob M; Mikhail A; Nowicki M; MacPhee I; Mysliwiec M; Smolenski O; Sułowicz W; Mayo M; Francisco C; Polu KR; Schatz PJ; Duliege AM
Clin J Am Soc Nephrol; 2011 Nov; 6(11):2579-86. PubMed ID: 21940838
[TBL] [Abstract][Full Text] [Related]
23. [Is the management of anemia in hemodialysis patients improving in France? Results of the DiaNE study].
Kessler M; Landais P; Canivet E; Yver L; Bataille P; Brillet G; Commenges B; Koné S
Nephrol Ther; 2009 Apr; 5(2):114-21. PubMed ID: 19042175
[TBL] [Abstract][Full Text] [Related]
24. Costs of managing anemia with erythropoiesis-stimulating agents during hemodialysis: a time and motion study.
Schiller B; Doss S; DE Cock E; Del Aguila MA; Nissenson AR
Hemodial Int; 2008 Oct; 12(4):441-9. PubMed ID: 19090867
[TBL] [Abstract][Full Text] [Related]
25. Anemia in renal disease: diagnosis and management.
Lankhorst CE; Wish JB
Blood Rev; 2010 Jan; 24(1):39-47. PubMed ID: 19833421
[TBL] [Abstract][Full Text] [Related]
26. Quality of life in CKD patients treated with erythropoiesis-stimulating agents.
Parfrey PS; Wish T
Am J Kidney Dis; 2010 Mar; 55(3):423-5. PubMed ID: 20189050
[No Abstract] [Full Text] [Related]
27. Lost without directions: lessons from the anemia debate and the drive study.
Spiegel DM; Chertow GM
Clin J Am Soc Nephrol; 2009 May; 4(5):1009-10. PubMed ID: 19357246
[TBL] [Abstract][Full Text] [Related]
28. A comprehensive vision for intravenous iron therapy.
Coyne DW
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
[TBL] [Abstract][Full Text] [Related]
29. Optimizing the management of renal anemia: challenges and new opportunities.
Locatelli F; Del Vecchio L
Kidney Int Suppl; 2008 Dec; (111):S33-7. PubMed ID: 19034323
[TBL] [Abstract][Full Text] [Related]
30. Adverse consequences with use of erythropoiesis-stimulating agents in anemia prompt release of guidelines to ensure safe use and maximize benefit.
Dharmarajan TS; Widjaja D
Geriatrics; 2008 Jun; 63(6):13-29. PubMed ID: 18512996
[TBL] [Abstract][Full Text] [Related]
31. Hemoglobin control, ESA resistance, and regular low-dose IV iron therapy: a review of the evidence.
Singh A
Semin Dial; 2009; 22(1):64-9. PubMed ID: 19175537
[TBL] [Abstract][Full Text] [Related]
32. Chronic kidney disease, anemia, and epoetin.
Mikhail A; Goldsmith D
N Engl J Med; 2007 Mar; 356(9):956-7; author reply 958-9. PubMed ID: 17338045
[No Abstract] [Full Text] [Related]
33. Correcting iron-restricted erythropoiesis and improving anemia in patients on hemodialysis: practical tips that can make a difference.
Easom A
Nephrol Nurs J; 2009; 36(5):529-37, 553. PubMed ID: 19856814
[TBL] [Abstract][Full Text] [Related]
34. Strategies for successfully managing the anemia of chronic kidney disease in the long-term care setting.
Germain MJ
Consult Pharm; 2008 Mar; 23 Suppl A():11-7. PubMed ID: 18454575
[TBL] [Abstract][Full Text] [Related]
35. Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia?
Kalantar-Zadeh K; Streja E; Miller JE; Nissenson AR
Adv Chronic Kidney Dis; 2009 Mar; 16(2):143-51. PubMed ID: 19233073
[TBL] [Abstract][Full Text] [Related]
36. Effect of route of EPO administration on hemodialysis arteriovenous vascular access failure: a randomized controlled trial.
Lee YK; Koo JR; Kim JK; Park II; Joo MH; Yoon JW; Noh JW; Vaziri ND
Am J Kidney Dis; 2009 May; 53(5):815-22. PubMed ID: 19324483
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of once-weekly intravenous administration of epoetin-beta as a maintenance treatment for anemia in Japanese hemodialysis patients: a multicenter, open-label clinical study.
Shigematsu T; Takami H; Shimizu T; Shimoyama H; Kim S; Hirose S; Sakai T; Kono T; Mochizuki T; Nishio K; Degawa H; Motomiya Y
Ther Apher Dial; 2008 Dec; 12(6):469-74. PubMed ID: 19140845
[TBL] [Abstract][Full Text] [Related]
38. Update on the use of erythropoiesis-stimulating agents (ESAs) for the management of anemia of multiple myeloma and lymphoma.
Katodritou E; Dimopoulos MA; Zervas K; Terpos E
Cancer Treat Rev; 2009 Dec; 35(8):738-43. PubMed ID: 19733008
[TBL] [Abstract][Full Text] [Related]
39. New anemia therapies: translating novel strategies from bench to bedside.
Macdougall IC
Am J Kidney Dis; 2012 Mar; 59(3):444-51. PubMed ID: 22192713
[TBL] [Abstract][Full Text] [Related]
40. Evolving regulatory landscape with erythropoiesis-stimulating agents and impact on managed care.
Fatodu H
Am J Manag Care; 2010 Mar; 16 Suppl Issues():S74-9. PubMed ID: 20297875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
